Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2013

Content (16 Articles)

Review

Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research

Michaela S. Tracy, Shoshana M. Rosenberg, Laura Dominici, Ann H. Partridge

Review

Everolimus: side effect profile and management of toxicities in breast cancer

Elisavet Paplomata, Amelia Zelnak, Ruth O’Regan

Open Access Preclinical Study

Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients

M. J. Engstrøm, S. Opdahl, A. I. Hagen, P. R. Romundstad, L. A. Akslen, O. A. Haugen, L. J. Vatten, A. M. Bofin

Open Access Preclinical Study

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics

Floris H. Groenendijk, Wilbert Zwart, Arno Floore, Stephanie Akbari, Rene Bernards

Preclinical Study

Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?

Michelle C. Specht, Cynthia L. Miller, Tara A. Russell, Nora Horick, Melissa N. Skolny, Jean A. O’Toole, Lauren S. Jammallo, Andrzej Niemierko, Betro T. Sadek, Mina N. Shenouda, Dianne M. Finkelstein, Barbara L. Smith, Alphonse G. Taghian

Preclinical Study

CX3CL1 expression is associated with poor outcome in breast cancer patients

Julia Y. S. Tsang, Yun-Bi Ni, Siu-Ki Chan, Mu-Min Shao, Ying-Kin Kwok, Kit-Wing Chan, Puay Hoon Tan, Gary M. Tse

Preclinical Study

HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions

Daniele Fanale, Viviana Bazan, Lidia Rita Corsini, Stefano Caruso, Lavinia Insalaco, Marta Castiglia, Giuseppe Cicero, Giuseppe Bronte, Antonio Russo

Clinical trial

Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial

Mohammed R. S. Keshtgar, Norman R. Williams, Max Bulsara, Christobel Saunders, Henrik Flyger, Jaime S. Cardoso, Tammy Corica, Neils Bentzon, Nikolaos V. Michalopoulos, David J. Joseph

Clinical Trial

Surgical impact of preoperative breast MRI in women below 40 years of age

Antonella Petrillo, Annamaria Porto, Roberta Fusco, Salvatore Filice, Paolo Vallone, Maria Rosaria Rubulotta, Franco Fulciniti, Maurizio Di Bonito, Massimiliano D’Aiuto, Immacolata Capasso, Rubina Manuela Trimboli, Francesco Sardanelli

Epidemiology

Clinical outcomes following nipple–areola-sparing mastectomy with immediate implant-based breast reconstruction: a 12-year experience with an analysis of patient and breast-related factors for complications

Alexandre Mendonça Munhoz, Cláudia Maria Aldrighi, Eduardo Montag, Eduardo Gustavo Arruda, José Mendes Aldrighi, Rolf Gemperli, Jose Roberto Filassi, Marcus Castro Ferreira

Epidemiology

Association between chronological change of reproductive factors and breast cancer risk defined by hormone receptor status: results from the Seoul Breast Cancer Study

Seokang Chung, Sue K. Park, Hyuna Sung, Nan Song, Wonshik Han, Dong-Young Noh, Sei-Hyun Ahn, Keun-Young Yoo, Ji-Yeob Choi, Daehee Kang

Epidemiology

Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women

Edoardo Botteri, Elisabetta Munzone, Nicole Rotmensz, Carlo Cipolla, Vincenzo De Giorgi, Barbara Santillo, Arnaldo Zanelotti, Laura Adamoli, Marco Colleoni, Giuseppe Viale, Aron Goldhirsch, Sara Gandini

Epidemiology

Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients

E. J. Bantema-Joppe, E. R. van den Heuvel, L. de Munck, G. H. de Bock, W. G. J. M. Smit, P. R. Timmer, W. V. Dolsma, L. Jansen, C. P. Schröder, S. Siesling, J. A. Langendijk, J. H. Maduro

Epidemiology

Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study

Martha L. Slattery, Esther M. John, Mariana C. Stern, Jennifer Herrick, Abbie Lundgreen, Anna R. Giuliano, Lisa Hines, Kathy B. Baumgartner, Gabriela Torres-Mejia, Roger K. Wolff

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine